Martin Kropff
- Hematology top 0.2%
- Molecular Biology top 5%
- Oncology top 2%
- Genetics top 2%
- Pathology and Forensic Medicine top 10%
- Co-authors
- Wolfgang E. BerdelJoachim KienastMeletios Α. DimopoulosRolf M. MestersTeresa PadróHelgi van de VeldeBerno DankbarRegine Leo
- Topics
- Multiple Myeloma Research and Treatments (59 papers)Cancer Treatment and Pharmacology (21 papers)Protein Degradation and Inhibitors (21 papers)
- Cited by
- HematologyOncologyGenetics
In The Last Decade
Martin Kropff
69 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Hematology 2.5k
- Molecular Biology 2.1k
- Oncology 1.7k
- Genetics 368
- Pathology and Forensic Medicine 183
Countries citing papers authored by Martin Kropff
This map shows the geographic impact of Martin Kropff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kropff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kropff more than expected).
Fields of papers citing papers by Martin Kropff
This network shows the impact of papers produced by Martin Kropff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kropff. The network helps show where Martin Kropff may publish in the future.
Co-authorship network of co-authors of Martin Kropff
This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kropff. A scholar is included among the top collaborators of Martin Kropff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kropff. Martin Kropff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 8 | |
| 3 | 18 | |
| 4 | 48 | |
| 5 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studybreakdown → | 661 |
| 6 | A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM) | 12 |
| 7 | 100 | |
| 8 | 157 | |
| 9 | 24 | |
| 10 | 4 | |
| 11 | 6 | |
| 12 | 312 | |
| 13 | 51 | |
| 14 | 12 | |
| 15 | Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm) | 7 |
| 16 | 23 | |
| 17 | 37 | |
| 18 | 28 | |
| 19 | 3 | |
| 20 | 96 |
About Martin Kropff
Martin Kropff is a scholar working on Hematology, Oncology and Genetics, having authored 69 papers that have together received 3.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (59 papers), Cancer Treatment and Pharmacology (21 papers) and Protein Degradation and Inhibitors (21 papers). The work is most often cited by research in Hematology (2.5k citations), Oncology (1.7k citations) and Genetics (368 citations). Martin Kropff has collaborated with scholars based in Germany, Italy and Greece. Frequent co-authors include Wolfgang E. Berdel, Joachim Kienast, Meletios Α. Dimopoulos, Rolf M. Mesters, Teresa Padró, Helgi van de Velde, Berno Dankbar, Regine Leo, Antonio Palumbo and Jesús F. San Miguel. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.